Recipharm’s proprietary molecule Erdosteine to be tested as part of COVID-19 treatment
Recipharm is pleased to announce that Erdosteine will be tested in a clinical study as an add-on treatment for COVID-19 patients. The clinical study, which began on 7[th] April, is being conducted in clinical centres actively involved in COVID-19 treatment in Milan and Bergamo. Both Milan and Bergamo are based in Lombardy, the Italian region most affected by the virus. The study, which involves around 100 patients affected by COVID-19 and discharged from hospitals, is evaluating if Erdosteine improves respiratory symptoms (dyspnea, cough, asthenia) and reduces the time to reach a